April 4, 2016
Nichi-Iko Pharmaceutical has acquired global rights to a biosimilar version of rituximab from South Korea’s Aprogen, the third biosimilar licensed from the partner, the Japanese generic major said on March 31. Since it concluded an accord regarding biosimilar R&D with...read more